Amgen Analysis: $164B Raised
What is Amgen?
Pioneer in biotechnology for serious illnesses
Employees
10001+
Founded
1980
Valuation
$164.25 billion
Revenue Growth Rate
7%
Product Features & Capabilities
- Innovative human therapeutics targeting serious illnesses
- Comprehensive pipeline of biologic medicines
- Advanced research in human and disease biology
- Clinical trial optimization using AI and data science
- Commitment to patient safety and product quality.
Use Cases
Treat serious illnesses with limited treatment options; Conduct clinical trials for new therapeutics; Optimize drug development through advanced research; Ensure patient safety and product quality; Engage in community investment and health equity initiatives.
Investment Focus
Amgen primarily focuses on four therapeutic areas: general medicine, rare disease, inflammation, and oncology. They aim to deliver innovative medicines that help people live longer, fuller, and happier lives.
Other Considerations
Publicly traded company with significant market presence; Recognized for sustainability and corporate responsibility; Engages in partnerships for research and community initiatives.
Latest Funding Round
Amgen borrowed $4 billion under a Term Loan Credit Agreement on October 6, 2023. This funding is part of a financial strategy related to the acquisition of Horizon Therapeutics, rather than a traditional funding round.
Regulatory Approvals
Amgen has received several regulatory approvals for its products and technologies, including: 1. LUMAKRAS (sotorasib) - The first KRASG12C inhibitor to receive regulatory approval in the U.S. under accelerated approval in May 2021. It has been approved for use in treating certain types of cancer. 2. Riabni (rituximab biosimilar) - Approved by the FDA for the treatment of adult patients with certain types of cancer, referencing the original Rituxan. 3. Uplizna - A CD19-targeted therapy for rare diseases, which has been involved in regulatory filings in the U.S. and other regions. 4. Biosimilar Applications - Amgen has had multiple biosimilar applications accepted by the FDA, including for products like ABP 501. These approvals reflect Amgen's commitment to developing innovative therapies for serious illnesses.
Awards Recognition
Amgen has received several awards and recognitions in the biotech field, including:
- Ranked #6 on Fortune's list of the World's Most Admired Companies within the biopharmaceutical peer group.
- The Amgen Biotech Experience was shortlisted for the Corporate Social Responsibility Programme of the Year at the Pharma Industry Awards 2024.
- The Amgen Biotech Experience won the Community Programme award in the multinational category at the annual Chambers of Ireland awards.
Key Innovations
Amgen has developed several key innovations and products in the biotech sector, including:
- Enbrel (etanercept) - A biologic drug used to treat autoimmune diseases such as rheumatoid arthritis.
- Prolia (denosumab) - Used for the treatment of osteoporosis in postmenopausal women.
- Xgeva (denosumab) - Approved for the prevention of skeletal-related events in patients with bone metastases.
- Aimovig (erenumab-aooe) - A treatment for migraine prevention.
- Aranesp (darbepoetin alfa) - Used to treat anemia associated with chronic kidney disease.
- Blincyto (blinatumomab) - A bispecific T-cell engager for the treatment of acute lymphoblastic leukemia.
- Neulasta (pegfilgrastim) - Used to reduce the risk of infection in patients undergoing chemotherapy.
- Repatha (evolocumab) - A PCSK9 inhibitor for lowering cholesterol levels.
Amgen is also known for its innovations in biologic medicines, utilizing advanced technologies and research methodologies to develop therapies for serious illnesses.
Partnerships
Amgen has established several significant partnerships and collaborations in the biotech industry, including:
- MediLink Therapeutics - A global clinical trial collaboration and supply agreement was announced to advance clinical trials. - Source
- Merck - Amgen and Merck became the first industry partners of an academic clinical trial diversity initiative, focusing on enhancing collaborations with local trial sites and communities. - Source
- BeiGene - A strategic collaboration to advance 20 medicines from Amgen's oncology pipeline in China and globally. - Source
- Neumora Therapeutics - A strategic R&D collaboration to accelerate novel precision therapies for brain diseases. - Source
- Generate Biomedicines - A multi-target research collaboration agreement, with an upfront funding of $50 million for initial programs. - Source
- Adaptive Biotechnologies - A partnership to develop a therapeutic to prevent or treat COVID-19. - Source
Find more companies like Amgen
See something that needs updating? Suggest edits to this profile.
